University of Massachusetts Chan Medical School

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Retrieved on: 
Tuesday, October 17, 2023
Investment, Food, Lupus nephritis, Division, Death, Cytarabine, NKG2D, Risk, Rituximab, IND, Safety, University, AML, Conference call, AID, Brattleboro Retreat, Autoimmune disease, Dialysis, FDA, B-cell lymphoma, Workforce, Department of Medicine – University of Pamplona, Lupus, ET, CAR, Immune system, Patient, End organ damage, Rheumatic Disease Clinics of North America, LN, Kidney disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SAN, MRD, NK, University of Massachusetts Chan Medical School, Parikh, Conference, Investigational New Drug, SLE, NHL, Pharmaceutical industry, Vaccine, Cryptocurrency, Nursing, LD, Rheumatology, Medicine

(1)

Key Points: 
  • (1)
    The multi-center, open label, dose escalation clinical trial will assess the safety and clinical activity of NKX019 in patients with refractory LN.
  • “The clearance of Nkarta’s IND for NKX019 in lupus nephritis is an important achievement for Nkarta, and we feel NK cell therapy is ideally suited for the treatment of autoimmune disease,” said Paul J. Hastings, President and CEO of Nkarta.
  • Nkarta announced today the opening of a new cohort in its Phase 1 study of NKX019 in r/r NHL.
  • Nkarta management will discuss its program in autoimmune disease and other corporate updates on Tuesday, October 17, at 8:00 a.m.

Coave Therapeutics appoints Leading World Experts to newly formed Scientific Advisory Board dedicated to its Genetic Medicine Delivery Platform

Retrieved on: 
Thursday, October 12, 2023
University of Pennsylvania, Knowledge, Doctor of Philosophy, Neuroscience, University of Massachusetts Chan Medical School, Education minister, CSO, Pediatrics, Stanford University School of Medicine, LDRI, Translational research, MD, Gene, United States Air Force Scientific Advisory Board, University, Duke University School of Medicine, Translation, Gene therapy, Université catholique de Louvain, Laboratory, AAV, Growth, Genetics, DSM-IV codes, DVM, LFCS, SAB, Patient, Vaccine, Management

Their collective expertise will also contribute to enhancing the ALIGATER™ platform and expanding its potential across viral (adeno-associated virus; AAV) and non-viral vector-based therapeutics, unlocking the potential to develop novel genetic medicines targeting serious diseases.

Key Points: 
  • Their collective expertise will also contribute to enhancing the ALIGATER™ platform and expanding its potential across viral (adeno-associated virus; AAV) and non-viral vector-based therapeutics, unlocking the potential to develop novel genetic medicines targeting serious diseases.
  • Lolita Petit, CSO of Coave Therapeutics commented, “We are absolutely thrilled to welcome our exceptional Scientific Advisory Board to the Coave team.
  • Each of these distinguished members has made profound contributions to the fields of genetic medicine, gene therapy, and neurosciences, bringing a unique depth of knowledge and experience to Coave.
  • We eagerly anticipate the opportunity to leverage their unique scientific insights to continue to advance our pipeline and ALIGATER platform.

NIIMBL Launches Viral Vector Program to Help Improve Patient Access to AAV Gene Therapy

Retrieved on: 
Tuesday, October 10, 2023
Vector (mathematics and physics), Hope, Government, Viral vector, University, Doctor of Philosophy, Ecosystem, Workforce, AAV, NIIMBL, Rare, University of Massachusetts Chan Medical School, Viral, Patient, Vaccine

"There are thousands of rare diseases, many of which could be candidates for AAV-based gene therapy.

Key Points: 
  • "There are thousands of rare diseases, many of which could be candidates for AAV-based gene therapy.
  • The initial structure of the Viral Vector Program will include:
    Additionally, a key component of the Viral Vector Program includes a parallel initiative in workforce development for key capabilities in AAV vector manufacturing and analytics.
  • NIIMBL will be hosting a webinar on the Viral Vector program on November 15, 2023.
  • To register for the webinar and to learn more about NIIMBL and the Viral Vector program, visit NIIMBL.org/ViralVector .

Healthiest 100 Workplaces in America - 2023 Winners

Retrieved on: 
Wednesday, October 4, 2023
University, Dallas Fort Worth International Airport, Insurance, College of the Holy Cross, CNO, Holy Cross, Cambia Health Solutions, National Association of Insurance Commissioners, Lincoln National Corporation, Public utility, Port of Portland, Witham Health Services, University of Massachusetts Chan Medical School, Treasury, International airport, Blue Shield, City, Health care, CNO Financial Group, Cole Resource Center, Blue Cross, Harris Health System, Healthiest State in the Nation Campaign, National Association, Benchmarking, Samaritan Health Services, Treasury Wine Estates, Nursing, Clothing, Sand, Citrus, Canal, Harbor, Frankincense, Lumber, Jet fuel, Cement

INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Every year, Healthiest Employers® names the Healthiest 100 Workplaces in America award, comprising regional applicants of various sizes, locations, and industries.

Key Points: 
  • INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Every year, Healthiest Employers® names the Healthiest 100 Workplaces in America award, comprising regional applicants of various sizes, locations, and industries.
  • The Healthiest 100 Workplaces in America for 2023 have been named by Healthiest Employers and Springbuk.
  • To qualify for the national award, applicants are also scored based on an additional section called "the Healthiest 100 Workplaces in America," which scores the applicant's essays and asks additional questions related to chronic conditions and workplace health.
  • Today, we currently host award ceremonies in over 45 regions across the country and applicants are not only eligible for local recognition, but also have the chance to earn a spot on the Healthiest 100 Workplaces in America.

NIH STUDY SUGGESTS MATERNAL INFLAMMATION RISK FACTORS ASSOCIATED WITH CHILDREN'S BEHAVIORAL AND EMOTIONAL REGULATION

Retrieved on: 
Monday, July 17, 2023
Infection, Pregnancy, Depression, University, Education, Anxiety, ECHO, Aggression, Risk, Inflammation, University of Massachusetts Chan Medical School, Bangladesh Technical Education Board, Mother, Overweight, Biophysical environment, Child Behavior Checklist, Mixed anxiety–depressive disorder, Smoking, CBCL, Emotional dysregulation, Nursing, Birth control, MD

DURHAM, N.C., July 17, 2023 /PRNewswire/ -- Maternal inflammation risk factors may be associated with dysregulation in children, according to a study funded by the Environmental influences on Child Health Outcomes (ECHO) Program at the National Institutes of Health.

Key Points: 
  • DURHAM, N.C., July 17, 2023 /PRNewswire/ -- Maternal inflammation risk factors may be associated with dysregulation in children, according to a study funded by the Environmental influences on Child Health Outcomes (ECHO) Program at the National Institutes of Health.
  • While inflammation is a normal bodily response to injury or infection, ECHO investigators wanted to learn whether factors linked to inflammation during pregnancy might be associated with dysregulation in children.
  • More youth with dysregulation (35%) were born to mothers with prenatal infections compared with 28% of youth without dysregulation.
  • Other maternal factors studied, including being overweight before pregnancy, attaining less education, and smoking during pregnancy, were associated with higher likelihoods of childhood dysregulation.

bioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics Symposium

Retrieved on: 
Thursday, June 15, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Vitamins, Supplements, Other Science, Research, Science, Clinical Trials, Sputum, Ruby Elzy, University, University of Massachusetts, Therapy, Senior, CD320, TCPP, Cancer, Lung cancer, RNA, DRS, BIAF, Cell, Lung, Bauta, Small RNA, Gene silencing, University of Massachusetts Chan Medical School, Flow cytometry, Sirna Therapeutics, LRP2, Death, Gene, Dietary supplement

Chan Medical School’s fifth annual RNA Therapeutics Symposium June 21-23, 2023, in Worcester, MA.

Key Points: 
  • Chan Medical School’s fifth annual RNA Therapeutics Symposium June 21-23, 2023, in Worcester, MA.
  • The RNA Therapeutics Institute at UMass leverages RNA biology and clinical research to develop new therapeutics for multiple diseases based on the fundamental mechanisms of cellular RNAs.
  • The vitamin B12 research follows the Company’s discovery that using small interfering RNA (siRNA) to knock down CD320 and LRP2 killed cancer cells in vitro without harming healthy cells.
  • bioAffinity Technologies’ noninvasive test for early-stage lung cancer, CyPath® Lung , incorporates TCPP to identify cell populations in sputum that indicate cancer is present in the lung.

AMERICAN ACADEMY OF DERMATOLOGY: HOW TO CARE FOR SKIN WITH VITILIGO

Retrieved on: 
Tuesday, June 13, 2023
Learning, Dihydroxyacetone, Hair, Depression, University, Skin, Skin cancer, Clothing, Light, Nail, SPF, Doctor of Philosophy, FAAD, Dermatology, UPF, Patient, Vitiligo, AAD, University of Massachusetts Chan Medical School, Risk, Immune system, Diagnosis, Sunburn, Burns, Health, Tanning, Mental health, Injury, Disease, Cosmetics, MD

ROSEMONT, Ill., June 13, 2023 /PRNewswire/ -- Vitiligo is a disease that causes the skin to lose its natural color, resulting in light or white patches of skin. This condition, which affects people of all ages and ethnicities, not only affects patients' skin, but also can cause low self-esteem and depression, and be associated with other medical conditions.

Key Points: 
  • "However, there are some ways people can care for themselves to prevent vitiligo from spreading."
  • In recognition of Vitiligo Awareness Month in June, Dr. Mahmoud and the AAD recommend people with vitiligo follow these skin wellness tips:
    Protect your skin from the sun.
  • Use makeup, self-tanner, or skin dyes if you'd like to add color to your skin.
  • This video is part of the AAD's "Your Dermatologist Knows" series, which offers tips people can use to properly care for their skin, hair, and nails.

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

Retrieved on: 
Thursday, May 18, 2023
Waldenström macroglobulinemia, Partnership, City of Hope, Mayo Clinic, Employment, Birmingham School of Law, Malignancy, University, GBM, CD20, Fred Hutchinson Cancer Research Center, Neoplasm, Biotechnology, Lead, University of Massachusetts Chan Medical School, Translation, Sale, WM, Security, CAR, PSCA, CDMO, Hematological Cancer Research Investment and Education Act, City, Waldenström, Acquisition, CGMP, Patient, Cancer, XSCID, Birmingham, Ecosystem, Nationwide, Mustang, IND, DSM-IV codes, Leiden University, Vaccine, Bank, Pharmaceutical industry, Fine chemical, Greater Boston

WORCESTER, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced a strategic update, including anticipated milestones for 2023. Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology. Additionally, Mustang announced a partnership with uBriGene (Boston) Biosciences Inc. (“uBriGene”), the U.S. subsidiary of uBriGene Group, a leading cell and gene therapy contract development and manufacturing organization (“CDMO”), which includes the sale of the Company’s development, manufacturing and analytical testing facility in Worcester, Massachusetts to uBriGene.

Key Points: 
  • Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology.
  • Additionally, Mustang announced a partnership with uBriGene (Boston) Biosciences Inc. (“uBriGene”), the U.S. subsidiary of uBriGene Group, a leading cell and gene therapy contract development and manufacturing organization (“CDMO”), which includes the sale of the Company’s development, manufacturing and analytical testing facility in Worcester, Massachusetts to uBriGene.
  • Subject to closing, the parties will enter into a manufacturing supply agreement, under which uBriGene will manufacture Mustang’s lead product candidates, including continuing to support MB-106 manufacturing for the ongoing multi-center Phase 1/2 trial.
  • I want to thank our manufacturing team for their dedication in building and growing our Worcester facility since it opened in 2018.

Could Fixing a Problem with the Heart Be Good for Your Brain?

Retrieved on: 
Wednesday, April 19, 2023
Amnesia, DSM-IV codes, Epilepsy, Heart, Concussion, Migraine, American Academy of Neurology, University, Cognitive deficit, AAN, Atrial fibrillation, Stroke, Deficit spending, American Academy, Sleep apnea, Brain, Attention, Research, Multiple sclerosis, Language, Kidney, Thought, University of Massachusetts Chan Medical School, Catheter ablation, DO, Dementia, Parkinson's disease, Risk, Nervous system, Annual general meeting, Memory, Alzheimer's disease, Social media, Medical imaging, Medical device, Pharmaceutical industry, Neurology

Catheter ablation uses radiofrequency through a tube into the heart to destroy small areas of heart tissue that may be causing the abnormal heartbeat.

Key Points: 
  • Catheter ablation uses radiofrequency through a tube into the heart to destroy small areas of heart tissue that may be causing the abnormal heartbeat.
  • "Our findings show that treatment with catheter ablation is linked to a reduced risk of cognitive impairment."
  • The study involved 887 people with an average age of 75 at the start of the study.
  • For more information about the American Academy of Neurology, visit AAN.com or find us on Facebook , Twitter , Instagram , LinkedIn and YouTube .

Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors

Retrieved on: 
Wednesday, April 19, 2023
Molecular biology, University of Massachusetts Chan Medical School, Advanced Management Program, Biotechnology, Drug development, University, Biochemistry, Doctor of Philosophy, Harvard University, Biogen, Howard Hughes Medical Institute, Patient, Naval Information Warfare Systems Command Program Executive Offices, Harvard Business School, Therapy, KROS, Management

“Dr.

Key Points: 
  • “Dr.
  • From July 2017 to January 2019, Dr. Seth was the Chief Operating Officer of Vir Biotechnology, Inc.
  • Prior to joining Vir, Dr. Seth was Senior Vice President and Global Head of the Biosimilars business for Biogen, Inc. since 2014.
  • She is also a graduate of the Advanced Management Program at Harvard Business School.